復宏漢霖(02696.HK)黃斑變性藥物HLX04-O上市註冊申請獲受理
復宏漢霖(02696.HK)公佈,近日HLX04-O用於治療溼性年齡相關性黃斑變性(wAMD)的上市註冊申請(NDA)獲國家藥品監督管理局(NMPA)藥品審評中心受理。
公司指,目前於中國境內上市的貝伐珠單抗產品均無溼性年齡相關性黃斑變性(wAMD)適應症。根據IQVIA CHPA的最新數據,2024年,於中國境內上市的針對溼性年齡相關性黃斑變性(wAMD)適應症的藥物的銷售額約爲49億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.